James Strauss

1.3k citations

69 papers · 837 indexed · 1 hit paper · h-index 14

Impact in

Immunology top 10%
- interferon and immune responses
- Immunotherapy and Immune Responses
- Immune Cell Function and Interaction
- Immune cells in cancer
Oncology top 10%
- Cancer Immunotherapy and Biomarkers
- CAR-T cell therapy research
- Pancreatic and Hepatic Oncology Research

Papers in ⓘ

Oncology 45
- Cancer Immunotherapy and Biomarkers 23
- CAR-T cell therapy research 9
- Pancreatic and Hepatic Oncology Research 8
- Cancer Treatment and Pharmacology 5
Biotechnology 13
- Cancer Research and Treatments 13

Co-authors: Talia Golan (2 shared papers)Kevin J. Harrington (2 shared papers)Joshua Brody (2 shared papers)Anuradha Khilnani (2 shared papers)Sašo Čemerski (1 shared paper)Archie Tse (1 shared paper)Aurélien Marabelle (1 shared paper)Eugene P. Frenkel (2 shared papers)
Journals: Journal of Clinical Oncology (28 papers)Annals of Oncology (9 papers)Cancer Research (5 papers)Clinical Cancer Research (2 papers)Journal for ImmunoTherapy of Cancer (2 papers)
Partner nations: United States United Kingdom Canada

In The Last Decade

James Strauss

66 papers receiving 817 citations

Hit Papers

align trajectories log scale

Phase I Study of SYNB1891, an Engineered E. coli Nissle Strain Expressing STING Agonist, with and without Atezolizumab in Advanced Malignancies 2023 · 84 citations

Peers

Countries citing papers authored by James Strauss

Since Specialization

Citations

This map shows the geographic impact of James Strauss's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by James Strauss with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites James Strauss more than expected).

Fields of papers citing papers by James Strauss

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by James Strauss. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by James Strauss. The network helps show where James Strauss may publish in the future.

Co-authors

The 25 scholars most cited alongside James Strauss, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with James Strauss Line = papers co-authored together James Strauss links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 69 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Preliminary results of the first-in-human (FIH) study of MK-1454, an agonist of stimulator of interferon genes (STING), as monotherapy or in combination with pembrolizumab (pembro) in patients with advanced solid tumors or lymphomas Annals of Oncology ·Kevin J. Harrington, Joshua Brody, M. Ingham, James Strauss, Sašo Čemerski, M. Wang, Archie Tse, Anuradha Khilnani, Aurélien Marabelle, Talia Golan	2018	201
2	Phase I Study of SYNB1891, an Engineered E. coli Nissle Strain Expressing STING Agonist, with and without Atezolizumab in Advanced Malignancies Clinical Cancer Research ·Jason J. Luke, Sarina A. Piha‐Paul, Theresa Medina, Claire F. Verschraegen, Mary Varterasian, Aoife M. Brennan, Richard J. Riese, Anna Sokolovska, James Strauss, David L. Hava, Filip Jankú Hit paper breakdown →	2023	84
3	Follicular Lymphoma Adjacent to Foreign Body Granulomatous Inflammation and Fibrosis Surrounding Silicone Breast Prosthesis The American Journal of Surgical Pathology ·Paul D. Cook, Barbara M. Osborne, Robert L. Connor, James Strauss	1995	69
4	Resection of a solid and papillary epithelial neoplasm of the pancreas following treatment with Cis‐platinum and 5‐fluorouracil: A case report Medical and Pediatric Oncology ·James Strauss, Victor J. Hirsch, Charles N. Rubey, M. L. Pollock	1993	45
5	THROMBOSIS AND HEMORRHAGE IN ONCOLOGY PATIENTS Hematology/Oncology Clinics of North America ·Rodger L. Bick, James Strauss, Eugene P. Frenkel	1996	43
6	Nemvaleukin alfa monotherapy and in combination with pembrolizumab in patients (pts) with advanced solid tumors: ARTISTRY-1. Journal of Clinical Oncology ·Ulka N. Vaishampayan, Piotr Tomczak, Jameel Muzaffar, Ira Winer, Seth Rosen, Christopher Hoimes, Aman Chauhan, Anna Spreafico, Karl D. Lewis, Débora S. Bruno, Olivier Dumas, David F. McDermott, James Strauss, Quincy S. Chu, Lucy Gilbert, Arvind Chaudhry, Julie R. Graham, Valentina Boni, Marc S. Ernstoff, Vamsidhar Velcheti	2022	30
7	Results of an ongoing phase 1/2a dose escalation study of HPN424, a tri-specific half-life extended PSMA-targeting T-cell engager, in patients with metastatic castration-resistant prostate cancer (mCRPC). Journal of Clinical Oncology ·Johann S. de Bono, Lawrence Fong, Tomasz M. Beer, Xīn Gào, Daniel M. Geynisman, Howard A. Burris, James Strauss, Kevin D. Courtney, David I. Quinn, David James VanderWeele, Yifah Yaron, Che‐Leung Law, Mark N. Stein	2021	28
8	Phase 1 first-in-human study of dalutrafusp alfa, an anti–CD73-TGF-β-trap bifunctional antibody, in patients with advanced solid tumors Journal for ImmunoTherapy of Cancer ·Anthony W. Tolcher, Michael S. Gordon, Kathleen M. Mahoney, Anna Seto, Marianna Zavodovskaya, Chia‐Hsiang Hsueh, Shuyan Zhai, Thomas Tarnowski, Juliane M. Jürgensmeier, Susanna Stinson, Ahmed A. Othman, Tianling Chen, James Strauss	2023	22
9	Extraction and quantification of daunomycin and doxorubicin in tissues Journal of Chromatography B Biomedical Sciences and Applications ·James Strauss, Richard L. Kitchens, Virginia W. Patrizi, Eugene P. Frenkel	1980	18
10	Incidentally discovered distant cutaneous metastasis of sacral chordoma: a case with variation in S100 protein expression (compared to the primary tumor) and review of the literature Journal of Cutaneous Pathology ·George R. Collins, Lydia R. Essary, James Strauss, Peter Hino, Clay J. Cockerell	2012	17
11	Mocetinostat in Combination With Durvalumab for Patients With Advanced NSCLC: Results From a Phase I/II Study Clinical Lung Cancer ·Melissa L. Johnson, James Strauss, Manish R. Patel, Edward B. Garon, Keith D. Eaton, Tavette Neskorik, Josée Morin, Richard C. Chao, Balázs Halmos	2023	17
12	Ph I/II study of oral selective AXL inhibitor bemcentinib (BGB324) in combination with erlotinib in patients with advanced EGFRm NSCLC: End of trial update. Journal of Clinical Oncology ·Lauren A. Byers, Kathryn A. Gold, Julio A. Peguero, Melissa L. Johnson, Jorge J. Nieva, Wael A. Harb, Alberto Chiappori, Igor I. Rybkin, James Strauss, David E. Gerber	2021	17
13	Nemvaleukin alfa, a modified interleukin-2 cytokine, as monotherapy and with pembrolizumab in patients with advanced solid tumors (ARTISTRY-1) Journal for ImmunoTherapy of Cancer ·Ulka N. Vaishampayan, Jameel Muzaffar, Ira Winer, Seth Rosen, Christoper J Hoimes, Aman Chauhan, Anna Spreafico, Karl D. Lewis, Débora S. Bruno, Olivier Dumas, David H. McDermott, James Strauss, Quincy S. Chu, Lucy Gilbert, Arvind Chaudhry, Emiliano Calvo, Rita P. Dalal, Valentina Boni, Marc S. Ernstoff, Vamsidhar Velcheti	2024	14
14	A phase 1, open label, dose escalation study of MGD009, a humanized B7-H3 x CD3 DART protein, in combination with MGA012, an anti-PD-1 antibody, in patients with relapsed or refractory B7-H3-expressing tumors. Journal of Clinical Oncology ·Sadhna Shankar, Alexander I. Spira, James Strauss, Liqin Liu, Ross La Motte‐Mohs, Tony T. Wu, Syd Johnson, Ezio Bonvini, Paul A. Moore, Jon M. Wigginton, Jim Vasselli	2018	13
15	Phase I expansion study of XMT-1536, a novel NaPi2b-targeting antibody-drug conjugate (ADC): Preliminary efficacy, safety, and biomarker results in patients with previously treated metastatic ovarian cancer (OC) or non-small cell lung cancer (NSCLC). Journal of Clinical Oncology ·Debra L. Richardson, Minal Barve, James Strauss, Susanna V. Ulahannan, Kathleen N. Moore, Erika Hamilton, Melissa L. Johnson, Kyriakos P. Papadopoulos, Corrine Zarwan, Charles Anderson, Joseph Buscema, Deborah B. Doroshow, William J. Edenfield, Ursula A. Matulonis, Timothy F. Burns, Dirk Huebner, Valerie M. Jansen, Rebecca Mosher, Donna Jarlenski, Anthony W. Tolcher	2020	13
16	Relationship of infusion duration to safety, efficacy, and pharmacodynamics (PD): Second part of a phase I-II study using VSV-IFNβ-NIS (VV1) oncolytic virus in patients with refractory solid tumors. Journal of Clinical Oncology ·Jaime R. Merchan, Manish R. Patel, Timothy P. Cripe, Matthew Old, James Strauss, Amber Thomassen, Rosa María Díaz, Kah Whye Peng, Stephen J. Russell, Luke Russell, Monica Reckner, Erol Wiegert, Alice Bexon, Steven Powell	2020	12
17	Manufacturing‐dependent change in biological activity of the TLR4 agonist GSK1795091 and implications for lipid A analog development Clinical and Translational Science ·Neeltje Steeghs, Aaron R. Hansen, Glenn J. Hanna, Elena Garralda, Haeseong Park, James Strauss, Michael Adam, Gossett A. Campbell, Jennifer Carver, Rachael Easton, Katherine Mays, Peter J. Skrdla, Herbert Struemper, Michael L. Washburn, Christopher Matheny, Sarina A. Piha‐Paul	2022	12
18	A phase II trial combining tumor-targeting TP53 gene therapy with gemcitabine/nab-paclitaxel as a second-line treatment for metastatic pancreatic cancer. Journal of Clinical Oncology ·Chris Leung, Minal Barve, Ming‐Shiang Wu, Kathleen F. Pirollo, James Strauss, Wei‐Chih Liao, Shih‐Hung Yang, Robert Nunan, Jana Adams, Joe B. Harford, Esther H. Chang	2021	11
19	Phase I and II Clinical Studies of the STING Agonist Ulevostinag with and without Pembrolizumab in Participants with Advanced or Metastatic Solid Tumors or Lymphomas Clinical Cancer Research ·Kevin J. Harrington, Stéphane Champiat, Joshua Brody, Byoung Chul Cho, Emanuela Romano, Talia Golan, John Hyngstrom, James Strauss, David Y. Oh, Aron Popovtzer, Carlos Gomez‐Roca, Ruth Perets, Sung‐Bae Kim, Deborah J. Wong, Steven Powell, Anuradha Khilnani, Thomas Jemielita, Qing Zhao, Runchen Zhao, Matthew Ingham	2025	10
20	A phase 1 dose-escalation and -expansion study of IMP7068, a WEE1 inhibitor, in patients with advanced solid tumors. Journal of Clinical Oncology ·Chia‐Chi Lin, Jaspreet Singh Grewal, David Sommerhalder, James Strauss, Li‐Yuan Bai, Lin Shen, Yu‐Min Yeh, Chih-Yi Hsieh, Sui Xiong Cai, Ye Tian, Huan Xia, Congcong Zhang, Baoyue Li, Ming Zhang, Ning Ma, Liping Zhao, Jie Ma, Huiyan Shi, Zhixin Yu	2022	9

About James Strauss

James Strauss is a scholar working on Oncology, Biotechnology, Immunology, Internal Medicine and Cancer Research, having authored 69 papers that have together received 837 indexed citations. Recurring topics across this work include Cancer Immunotherapy and Biomarkers (23 papers), Cancer Research and Treatments (13 papers), Immunotherapy and Immune Responses (10 papers), CAR-T cell therapy research (9 papers), interferon and immune responses (9 papers), Virus-based gene therapy research (8 papers), Pancreatic and Hepatic Oncology Research (8 papers) and Cancer Treatment and Pharmacology (5 papers). The work is most often cited by research in Immunology (370 citations), Oncology (394 citations), Biotechnology (45 citations), Internal Medicine (19 citations) and Cancer Research (76 citations). James Strauss has collaborated with scholars based in United States, United Kingdom and Canada. Frequent co-authors include Talia Golan, Kevin J. Harrington, Joshua Brody, Anuradha Khilnani, Sašo Čemerski, Archie Tse, Aurélien Marabelle, Eugene P. Frenkel, Barbara M. Osborne and Rodger L. Bick. Their work appears in journals such as Journal of Clinical Oncology, Annals of Oncology, Cancer Research, Clinical Cancer Research and Journal for ImmunoTherapy of Cancer.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact